PMV Pharmaceuticals, Inc. reported a net loss of $18.1 million for the second quarter of 2026, a decrease from the $21.2 million loss recorded in the same period of the previous year. For the first half of 2026, the company incurred a net loss of $36.1 million, compared to a loss of $38.6 million for the first half of 2025. The reduction in losses is attributed to a decrease in operating expenses, which totaled $18.9 million for the second quarter of 2026, down from $22.9 million in the prior year. Research and development expenses were $14.7 million for the quarter, a decline from $18.4 million in the same quarter of 2025, primarily due to reduced contract research organization costs associated with the advancement of the lead product candidate, rezatapopt.
As of June 30, 2026, PMV Pharmaceuticals reported total assets of $82.1 million, a significant decrease from $116.6 million at the end of 2025. The decline in assets was driven by a reduction in cash and cash equivalents, which fell to $12.5 million from $38.0 million at the end of the previous year. Marketable securities also decreased to $67.0 million from $75.0 million. The company's accumulated deficit increased to $482.6 million, reflecting ongoing operational losses since its inception. The company’s current liabilities decreased slightly to $10.6 million from $11.4 million, contributing to a working capital of $70.8 million, down from $103.8 million.
In terms of strategic developments, PMV Pharmaceuticals continues to advance its clinical programs, particularly the Phase 1/2 clinical trial for rezatapopt, which targets patients with specific p53 mutations. The company received FDA Fast Track designation for rezatapopt in October 2020 and has made significant progress, including a recent meeting with the FDA to align on the Phase 2 trial design. The company plans to submit a New Drug Application for accelerated approval for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Operationally, PMV Pharmaceuticals has not generated any revenue from product sales to date and does not anticipate doing so in the near future. The company’s ability to continue operations is contingent upon securing additional funding, as management has expressed substantial doubt regarding its ability to continue as a going concern without further financing. The company has approximately $113.8 million available for future issuances under its at-the-market offering program, which it may utilize to support ongoing operations and development efforts.
Looking ahead, PMV Pharmaceuticals expects to incur significant operating losses as it continues to invest in research and development, regulatory approvals, and potential commercialization of its product candidates. The company is actively exploring various funding options, including public or private equity, debt financing, and strategic collaborations, to ensure it can meet its operational needs and advance its clinical programs.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, a common driver in over half of all cancers. Its lead candidate, rezatapopt, aims to structurally correct specific p53 mutations, such as Y220C, across multiple tumor types. The company advances tumor-agnostic, gene-specific treatments through clinical trials, leveraging genomic sequencing and targeted drug development to improve cancer patient outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov